Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 7.32 USD 2.23% Market Closed
Market Cap: 395.1m USD

Intrinsic Value

The intrinsic value of one FULC stock under the Base Case scenario is 2.47 USD. Compared to the current market price of 7.32 USD, Fulcrum Therapeutics Inc is Overvalued by 66%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

FULC Intrinsic Value
2.47 USD
Overvaluation 66%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Fulcrum Therapeutics Inc

Valuation History Unavailable

Historical valuation for FULC cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare FULC to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about FULC?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Fulcrum Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Fulcrum Therapeutics Inc

Current Assets 249.9m
Cash & Short-Term Investments 241m
Receivables 3.3m
Other Current Assets 5.6m
Non-Current Assets 10.8m
PP&E 9.6m
Other Non-Current Assets 1.2m
Efficiency

Free Cash Flow Analysis
Fulcrum Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Fulcrum Therapeutics Inc

Revenue
80m USD
Operating Expenses
-99.8m USD
Operating Income
-19.8m USD
Other Expenses
10.1m USD
Net Income
-9.7m USD
Fundamental Scores

FULC Profitability Score
Profitability Due Diligence

Fulcrum Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
32/100
Profitability
Score

Fulcrum Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

FULC Solvency Score
Solvency Due Diligence

Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Fulcrum Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FULC Price Targets Summary
Fulcrum Therapeutics Inc

Wall Street analysts forecast FULC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FULC is 7.72 USD with a low forecast of 2.02 USD and a high forecast of 12.6 USD.

Lowest
Price Target
2.02 USD
72% Downside
Average
Price Target
7.72 USD
6% Upside
Highest
Price Target
12.6 USD
72% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Fulcrum Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for FULC is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

FULC Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one FULC stock?

The intrinsic value of one FULC stock under the Base Case scenario is 2.47 USD.

Is FULC stock undervalued or overvalued?

Compared to the current market price of 7.32 USD, Fulcrum Therapeutics Inc is Overvalued by 66%.

Back to Top